Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics (VRDN)
NASDAQ:VRDN
Total Valuation
Viridian Therapeutics has a market cap or net worth of $1.10B. The enterprise value is $1.03B.
Market Cap$1.10B
Enterprise Value$1.03B
Share Statistics
Viridian Therapeutics has 81,484,950 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding81,484,950
Owned by Insiders4.26%
Owned by Institutions0.28%
Financial Efficiency
Viridian Therapeutics’s return on equity (ROE) is -0.40 and return on invested capital (ROIC) is -43.02%.
Return on Equity (ROE)-0.40
Return on Assets (ROA)-0.36
Return on Invested Capital (ROIC)-43.02%
Return on Capital Employed (ROCE)-0.43
Revenue Per Employee2.11K
Profits Per Employee-1.89M
Employee Count143
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Viridian Therapeutics is -4.82. Viridian Therapeutics’s PEG ratio is 0.19.
PE Ratio-4.82
PS Ratio4117.42
PB Ratio1.94
Price to Fair Value1.94
Price to FCF-5.59
Price to Operating Cash Flow-5.60
PEG Ratio0.19
Income Statement
In the last 12 months, Viridian Therapeutics had revenue of 302.00K and earned -269.95M in profits. Earnings per share was -3.98.
Revenue302.00K
Gross Profit302.00K
Operating Income-299.04M
Pretax Income-269.95M
Net Income-269.95M
EBITDA-266.36M
Earnings Per Share (EPS)-3.98
Cash Flow
In the last 12 months, operating cash flow was -232.32M and capital expenditures -511.00K, giving a free cash flow of -232.83M billion.
Operating Cash Flow-232.32M
Free Cash Flow-232.83M
Free Cash Flow per Share-2.86
Dividends & Yields
Viridian Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.71
52-Week Price Change-0.74%
50-Day Moving Average14.50
200-Day Moving Average18.06
Relative Strength Index (RSI)49.53
Average Volume (3m)977.99K
Important Dates
Viridian Therapeutics upcoming earnings date is May 7, 2025, TBA Not Confirmed.
Last Earnings DateFeb 27, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend Date―
Financial Position
Viridian Therapeutics as a current ratio of 15.43, with Debt / Equity ratio of 3.14%
Current Ratio15.43
Quick Ratio15.43
Debt to Market Cap0.02
Net Debt to EBITDA0.29
Interest Coverage Ratio-98.17
Taxes
In the past 12 months, Viridian Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Viridian Therapeutics EV to EBITDA ratio is -4.59, with an EV/FCF ratio of -5.25.
EV to Sales4.05K
EV to EBITDA-4.59
EV to Free Cash Flow-5.25
EV to Operating Cash Flow-5.26
Balance Sheet
Viridian Therapeutics has $717.58M in cash and marketable securities with $697.06K in debt, giving a net cash position of -$696.49M billion.
Cash & Marketable Securities$717.58M
Total Debt$697.06K
Net Cash-$696.49M
Net Cash Per Share-$8.55
Tangible Book Value Per Share$9.89
Margins
Gross margin is -1931.79%, with operating margin of -99018.21%, and net profit margin of -89387.09%.
Gross Margin-1931.79%
Operating Margin-99018.21%
Pretax Margin-89387.09%
Net Profit Margin-89387.09%
EBITDA Margin-88199.67%
EBIT Margin-88378.48%
Analyst Forecast
The average price target for Viridian Therapeutics is $41.11, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$41.11
Price Target Upside204.52% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast-3.82%
EPS Growth Forecast29.10%